Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab phase IV study of joint health, physical activity, and quality of life in hemophilia A
2020-005092-13Phase 4Terminated
- Sponsor
- Roche
- Start
- Sep 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Roche. Primary endpoint: Joint status over time based on centrally reviewed HEAD-US scores. Started Sep 2021; status: terminated.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2020-005092-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005092-13.